Hairfolliclestemcells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
Hairfollicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hairfolliclestemcells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
A Swiss product called Redensyl, which is supposed to target hairfolliclestemcells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
PP405, a topical LDH inhibitor, has shown to stimulate hairfolliclestemcell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.